Proliferative diabetic retinopathy (PDR) remains one of the most visually threatening complications of diabetes mellitus, accounting for a substantial proportion of preventable blindness among working-age adults worldwide. The pathogenesis of PDR involves progressive retinal ischemia that triggers the release of vascular endothelial growth factor (VEGF), leading to aberrant neovascularization on the retinal surface and optic disc. These new vessels are fragile and prone to hemorrhage, ultimately causing vitreous hemorrhage, tractional retinal detachment, and neovascular glaucoma if left untreated. Understanding the nuanced differences in how PDR presents and progresses in patients with type 1 versus type 2 diabetes is critical for clinicians, as it informs screening schedules, treatment timing, and long‑term management strategies.

Understanding Proliferative Diabetic Retinopathy

PDR represents the advanced stage of diabetic retinopathy, defined by the presence of neovascularization on the retina, optic disc, or iris. It develops as a consequence of chronic hyperglycemia, which damages retinal capillaries through several biochemical pathways, including accumulation of advanced glycation end‑products, activation of protein kinase C, and increased oxidative stress. Capillary occlusion leads to retinal non‑perfusion and hypoxia, upregulating pro‑angiogenic factors such as VEGF. The resulting new blood vessels are structurally abnormal, lacking pericytes and tight junctions, which explains their tendency to leak and bleed.

Epidemiologically, PDR affects approximately 5–10% of the global diabetic population, but the lifetime risk varies significantly by diabetes type. In type 1 diabetes, nearly 60% of patients will develop some form of retinopathy within 20 years of diagnosis, and 30–40% of those will progress to PDR. In type 2 diabetes, the prevalence of PDR is lower, but because the disease is far more common, the absolute number of PDR cases is higher. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) and more recent studies have clarified these epidemiological patterns. Additionally, the American Academy of Ophthalmology Preferred Practice Patterns provide evidence‑based screening and management guidelines that reflect these differences.

Key Differences Between Type 1 and Type 2 Diabetes in PDR

Onset and Progression

Type 1 diabetes typically presents in childhood, adolescence, or young adulthood, and the cumulative exposure to hyperglycemia is the primary driver of retinopathy. Retinopathy is rarely present at diagnosis but begins to appear after 3–5 years of disease, with PDR emerging after 10–15 years in many patients. In type 2 diabetes, the onset is often insidious, and patients may have undiagnosed hyperglycemia for years before clinical recognition. Consequently, up to 20% of patients newly diagnosed with type 2 diabetes already have some degree of retinopathy, and PDR can be present at diagnosis or develop within a shorter time frame relative to diabetes duration.

Risk Factor Profiles

While poor glycemic control (elevated HbA1c) is the most powerful modifiable risk factor in both types, other factors amplify PDR risk differently. Hypertension is a particularly strong risk factor in type 2 diabetes, driving progression through increased hydrostatic pressure in already‑compromised retinal vessels. Dyslipidemia, especially elevated triglycerides and low HDL cholesterol, is also more strongly associated with retinopathy severity in type 2 diabetics. Conversely, patients with type 1 diabetes often have fewer metabolic comorbidities at younger ages, making the duration of diabetes and the magnitude of hyperglycemia the predominant determinants of PDR risk. Additional risk factors common to both types include nephropathy, microalbuminuria, and pregnancy, which can accelerate progression of PDR in either population.

Prevalence and Incidence Data

Precise incidence rates have been documented in major cohort studies. The Diabetes Control and Complications Trial (DCCT) and its Epidemiology of Diabetes Interventions and Complications (EDIC) follow‑up showed that intensive glycemic control in type 1 diabetes reduced the long‑term risk of PDR by nearly 50%. For type 2 diabetes, the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated similar benefits of intensive control on microvascular outcomes. However, absolute PDR risk remains substantially higher in type 1 diabetes at any given duration, due to the earlier onset and longer lifetime exposure to hyperglycemia.

Identifying PDR in Diabetic Patients

Early identification of PDR is essential because treatments are most effective when initiated before significant vision loss occurs. The transition from non‑proliferative diabetic retinopathy (NPDR) to PDR is often asymptomatic; patients may notice floaters, flashes, or sudden vision loss only after vitreous hemorrhage has occurred. Therefore, systematic screening using both clinical examination and advanced imaging is paramount.

Clinical Examination Techniques

The gold standard for PDR detection is a dilated fundus examination using slit‑lamp biomicroscopy with a hand‑held lens (e.g., 78D or 90D) or indirect ophthalmoscopy. The clinician systematically inspects the posterior pole, optic disc, and retinal periphery for signs of neovascularization. In type 1 diabetes, neovascularization often begins at the optic disc (NVD), while in type 2 diabetes, it may appear more commonly in the retinal periphery (NVE). However, these patterns are not absolute. Examination should also look for vitreous hemorrhage, preretinal hemorrhage, and fibrous proliferation. The presence of any neovascularization classifies the eye as having PDR, even without hemorrhage.

The Role of Diagnostic Imaging

Optical coherence tomography (OCT) primarily assesses macular edema but can reveal additional features, such as vitreomacular traction, that influence treatment decisions. Wide‑field fluorescein angiography (FA) is invaluable for detecting peripheral retinal ischemia and subtle neovascularization not visible on exam. FA reveals areas of capillary non‑perfusion, microaneurysm leakage, and shunting, providing a road map for targeted laser photocoagulation. In recent years, ultra‑widefield FA has become the standard for comprehensive assessment. Optical coherence tomography angiography (OCTA) is a non‑invasive alternative that can detect neovascular complexes without dye injection, though it has limitations in visualizing peripheral lesions. For both type 1 and type 2 patients, annual dilated exams are recommended; more frequent follow‑up (every 3–6 months) is indicated when NPDR is severe or PDR is present.

Clinical Signs to Watch For

  • New vessels on the optic disc (NVD) or elsewhere in the retina (NVE)
  • Vitreous or preretinal hemorrhage — the most common presenting sign
  • Fibrous tissue proliferation associated with neovascularization
  • Tractional retinal detachment as fibrous bands contract
  • Neovascularization of the iris (NVI) and angle, leading to neovascular glaucoma

Management Strategies for PDR in Type 1 Versus Type 2 Diabetes

Management of PDR is a two‑pronged approach: local ophthalmic treatment aimed at eradicating neovascularization and systemic treatment to correct the underlying metabolic abnormalities. The choice and timing of therapy depend on the severity of PDR, the presence of macular edema, the patient’s age, and the type of diabetes.

Ophthalmic Treatments

Anti‑VEGF Therapy

Intravitreal anti‑VEGF agents (ranibizumab, aflibercept, bevacizumab) are now first‑line therapy for PDR, especially when associated with diabetic macular edema. Several landmark trials, including DRCR.net Protocol S and PANORAMA, have shown that anti‑VEGF monotherapy can achieve regression of neovascularization equal to or better than panretinal photocoagulation (PRP), with fewer visual field defects and less risk of macular edema exacerbation. In younger patients with type 1 diabetes, anti‑VEGF injections may be preferred to preserve peripheral visual field and avoid the long‑term effects of laser scarring. For type 2 patients, especially those with dense hemorrhage or extensive peripheral ischemia, a combination of anti‑VEGF and PRP may be warranted. Compliance with frequent follow‑up and injection scheduling is a challenge in both populations but is often more manageable in younger, more motivated type 1 patients.

Panretinal Photocoagulation (PRP)

PRP has been the standard of care for PDR for decades. Laser burns are applied to the peripheral retina to reduce the ischemic drive for neovascularization. While highly effective in causing regression of new vessels, PRP inflicts collateral damage—including night vision loss, constriction of visual field, and exacerbation of macular edema. In type 1 diabetes, where patients are younger and have a longer lifetime ahead, the side‑effect profile of PRP is especially concerning. Therefore, current guidelines recommend reserving PRP for cases where anti‑VEGF therapy is not feasible, or for high‑risk PDR with extensive neovascularization. In type 2 diabetes, many patients are older and have pre‑existing visual field limitations; PRP may be used more readily when anti‑VEGF resources are limited.

Surgical Intervention

Pars plana vitrectomy is indicated for persistent vitreous hemorrhage that does not clear after 1–3 months, for tractional retinal detachment involving or threatening the macula, and for severe fibrovascular proliferation. In type 1 diabetes, vitrectomy may be required earlier in the disease course because of more aggressive neovascularization and the development of taut fibrotic membranes. In type 2 diabetes, vitrectomy is often performed later, and the presence of concurrent systemic diseases (e.g., chronic kidney disease, cardiovascular disease) increases surgical risk. Advances in small‑gauge vitrectomy techniques have improved outcomes, but postoperative complications such as recurrent hemorrhage and macular edema remain higher in diabetic patients.

Systemic Control

Aggressive management of modifiable risk factors is the backbone of PDR prevention and treatment in both diabetes types. Glycemic control — targeting an HbA1c of less than 7% (53 mmol/mol) in most adults — slows the progression of retinopathy and reduces the need for ophthalmic intervention. However, in patients with type 2 diabetes who have advanced PDR, rapid improvements in glycemic control may paradoxically worsen retinopathy transiently (the “early worsening” phenomenon), necessitating close ophthalmologic monitoring during the first 6–12 months of intensified therapy. Blood pressure control — a target of <130/80 mmHg — is equally important. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study confirmed that intensive blood pressure lowering reduced the risk of PDR progression in type 2 diabetes. Lipid management with statins, particularly in type 2 diabetes, has been shown to reduce hard exudate formation and may modestly slow retinopathy progression. In type 1 diabetes, dyslipidemia is less prevalent, but high LDL remains a risk factor. Additionally, smoking cessation, nephropathy management, and control of sleep apnea can contribute to overall retinal health.

Special Considerations by Diabetes Type

Type 1 Diabetes in Pediatric and Young Adult Patients

Children and adolescents with type 1 diabetes require special screening protocols because of their long life expectancy and the high cumulative risk of PDR. The American Diabetes Association recommends the first dilated eye exam within 5 years of type 1 diabetes diagnosis and then annually, with more frequent exams if retinopathy is present. Pregnant women with type 1 diabetes are at particularly high risk for rapid progression of PDR during the second and third trimesters; they require eye exams each trimester and for several months postpartum. Anti‑VEGF use in pregnancy is generally avoided due to unknown teratogenic effects, making PRP the safer option during gestation. For young patients who develop PDR, treatment decisions must weigh the lifelong burden of repeated injections (and the psychosocial impact) against the consequences of laser. A shared decision‑making approach is essential.

Type 2 Diabetes in Older Adults

Older patients with type 2 diabetes often have multiple comorbidities that complicate PDR management. Reduced life expectancy may shift the goal from aggressive treatment toward preservation of existing vision and quality of life. For patients with limited mobility or transportation access, PRP may be preferred over multiple anti‑VEGF injections. Cataract surgery in patients with PDR can trigger progression of neovascularization or macular edema; careful timing and perioperative anti‑VEGF prophylaxis are required. Moreover, the economic burden of anti‑VEGF therapy can be substantial, and insurance coverage considerations may influence treatment choices. In older type 2 diabetics, concomitant cardiovascular and renal disease often limits the use of certain systemic medications (e.g., metformin is safe but thiazolidinediones have been associated with worsening macular edema).

Emerging Therapies and Future Directions

The landscape of PDR management is evolving rapidly. Sustained‑release drug delivery systems — such as the intravitreal fluocinolone acetonide implant and port delivery systems for ranibizumab — aim to reduce injection frequency and improve compliance. Studies are also exploring the use of the Akt/TOR pathway inhibitors and gene therapy targeting VEGF. The role of artificial intelligence (AI) in screening for PDR from fundus photographs is already being adopted in telemedicine programs, potentially increasing access in underserved areas. For type 1 diabetes, closed‑loop insulin pump systems that maintain tighter glycemic control may reduce the incidence of PDR over the long term. For type 2 diabetes, newer classes of glucose‑lowering medications, notably the GLP‑1 receptor agonists and SGLT‑2 inhibitors, show promise in slowing retinopathy progression through beneficial effects on the retinal microvasculature beyond their glycemic effects.

Conclusion

Proliferative diabetic retinopathy remains a serious, vision‑threatening complication of both type 1 and type 2 diabetes. The differences in onset, risk factors, and progression between these two populations demand tailored approaches to screening and treatment. In type 1 diabetes, early‑onset disease and long duration drive PDR risk, making meticulous glycemic control and diligent surveillance from a young age critical. In type 2 diabetes, the presence of multiple metabolic comorbidities — hypertension, dyslipidemia, and often a history of undiagnosed hyperglycemia — requires aggressive systemic management in addition to local ophthalmic therapy. Modern PDR therapy has moved from sole reliance on laser to a paradigm that prioritizes anti‑VEGF injections, with surgical options reserved for advanced cases. By understanding the distinct characteristics of PDR in type 1 versus type 2 diabetes, clinicians can implement personalized treatment plans, improve adherence, and ultimately preserve the sight of millions of patients worldwide.